The use of GLP-1 agonists and, more recently, dual and triple GLP-1/GIP and GLP-1/GIP/glucagon agonists has been proven to be a useful therapy for treating T2DM and obesity (10). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.